Twynsta is a drug owned by Boehringer Ingelheim Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 07, 2014. Details of Twynsta's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5591762 | Benzimidazoles useful as angiotensin-11 antagonists |
Jan, 2014
(11 years ago) |
Expired
|
FDA has granted several exclusivities to Twynsta. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Twynsta, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Twynsta.
Exclusivity Information
Twynsta holds 1 exclusivities. All of its exclusivities have expired in 2012. Details of Twynsta's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Oct 16, 2012 |
US patents provide insights into the exclusivity only within the United States, but Twynsta is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Twynsta's family patents as well as insights into ongoing legal events on those patents.
Twynsta's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Twynsta's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 07, 2014 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Twynsta Generic API suppliers:
Amlodipine Besylate; Telmisartan is the generic name for the brand Twynsta. 4 different companies have already filed for the generic of Twynsta, with Alembic having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Twynsta's generic
Alternative Brands for Twynsta
Twynsta which is used for managing high blood pressure., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbott |
| |||||||||||||||
| Abbvie |
| |||||||||||||||
| Adhera |
| |||||||||||||||
| Allergan |
| |||||||||||||||
| Ani Pharms |
| |||||||||||||||
| Azurity |
| |||||||||||||||
| Boehringer Ingelheim |
| |||||||||||||||
| Cosette |
| |||||||||||||||
| Noden Pharma |
| |||||||||||||||
| Novartis |
| |||||||||||||||
| Upjohn |
| |||||||||||||||
| Waylis Therap |
| |||||||||||||||
About Twynsta
Twynsta is a drug owned by Boehringer Ingelheim Pharmaceuticals Inc. It is used for managing high blood pressure. Twynsta uses Amlodipine Besylate; Telmisartan as an active ingredient. Twynsta was launched by Boehringer Ingelheim in 2009.
Approval Date:
Twynsta was approved by FDA for market use on 16 October, 2009.
Active Ingredient:
Twynsta uses Amlodipine Besylate; Telmisartan as the active ingredient. Check out other Drugs and Companies using Amlodipine Besylate; Telmisartan ingredient
Treatment:
Twynsta is used for managing high blood pressure.
Dosage:
Twynsta is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 5MG BASE;40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET | Discontinued | ORAL |
| EQ 10MG BASE;40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET | Discontinued | ORAL |
| EQ 5MG BASE;80MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET | Discontinued | ORAL |
| EQ 10MG BASE;80MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET | Discontinued | ORAL |